[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351226-105":59,"doc-detail-351226-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","short-term-hormonal-modulation-with-mifepristone-does-not-induce-oncogenic-changes-in-the-endometrium-of-brca12-pathogenic-variant-carriers","Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers","","Progesterone receptor antagonists such as mifepristone have been explored for breast cancer prevention in BRCA1/2 pathogenic variant carriers, but endometrial safety remains insufficiently defined due to concerns about unopposed estrogen. A randomized, double-blind, placebo-controlled trial evaluated secondary short-term effects after three months of treatment. Paired biopsies from participants were analyzed with transcriptomic, DNA methylation, and cell-type deconvolution methods. Results show treatment-induced amenorrhea without epithelial cell proportion increases and no molecular signatures of oncogenic transformation; cancer-associated methylation and gene expression indices remained stable. These findings support endometrial safety, while long-term studies are needed.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/short-term-hormonal-modulation-with-mifepristone-does-not-induce-oncogenic-changes-in-the-endometrium-of-brca12-pathogenic-variant-carriers/351226/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/short-term-hormonal-modulation-with-mifepristone-does-not-induce-oncogenic-changes-in-the-endometrium-of-brca12-pathogenic-variant-carriers/351226.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is mifepristone being studied for breast cancer prevention in BRCA1/2 pathogenic variant carriers?","Question",{"text":113,"@type":114},"Progesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, especially in high-risk populations like BRCA1/2 pathogenic variant carriers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What concern links mifepristone use to potential endometrial cancer risk?",{"text":118,"@type":114},"Because mifepristone can theoretically cause unopposed estrogen exposure in the setting of impaired DNA repair, it raises concerns about possible endometrial carcinogenesis.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main short-term endometrial findings after three months of treatment?",{"text":122,"@type":114},"Mifepristone induced amenorrhea in treated participants without increasing epithelial cell proportions, and multi-omics analyses showed no molecular signatures consistent with oncogenic transformation; endometrial cancer–associated DNA methylation and gene expression indices stayed stable.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351226,1790240527,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","A Nature Portfolio journal  \n[https://doi.org/10.1038/s43856-026-01412-0](https://doi.org/10.1038/s43856-026-01412-0)  \n\n| Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers\u003Cbr> Check for updates |  |  |\n| --- | --- | --- |\n| Martin Widschwendter  1,2,3,4,5,10, Chiara Herzog 2,3,10, Mohammed Fatih Rasul1,6, Nageswara Rao Boggavarapu1, Elisa Redl 2,3, Deborah Utjés1,7, Angelique Flöter Rådestad1,8, Kristina Gemzell-Danielsson  1,7,10 & Twana Alkasalias  1,9,10  |  |  |\n| Abstract Plain language summary |  |  |\n| Background Progesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, particularly in high-risk populations such as BRCA1/2 pathogenic variant carriers. However, their impact on endometrial safety remainsinsufﬁciently characterized, raising concerns about unopposed oestrogen stimulation in the setting of impaired DNA repair. This study reports secondary outcomes evaluating shortterm endometrial effects of mifepristone in this high-risk population.\u003Cbr>Methods We previously conducted a randomized, double-blind, placebo-controlled trial (NCT01898312) involving 45 premenopausal women with BRCA1/2 pathogenic variants. Participants received mifepristone (50 mg every other day, n = 30) or a non-hormonal comparator (n = 15) for three months. Here we present secondary outcomes from the trial:\u003Cbr>Paired endometrial biopsies from a subset of 14 participants were analysed using transcriptomic, DNA methylation, and cell-type deconvolution methods. Statistical comparisons were performed using paired and unpaired Wilcoxon tests.\u003Cbr>Results Here we show that mifepristone induces amenorrhea in all treated participants without increasing epithelial cell proportions, the compartment most relevant to endometrial carcinogenesis. Multi-omics analyses reveal no molecular signatures consistent with oncogenic transformation. DNA methylation and gene expression indices associated with endometrial cancer remain stable after treatment, even after adjusting for age and cell composition.\u003Cbr>Conclusions Short-term mifepristone exposure does not produce molecular changes linked to endometrial carcinogenesis in BRCA1/2 pathogenic variant carriers. These ﬁndings provide important safety data for the future development of progesterone receptor modulators in cancer prevention. Long-term studies are needed to conﬁrm these observations. |  | Women who have inherited different versions (mutations) of the BRCA1 orBRCA2 gene are more likely to get breast cancer. Medicines that block the activity of the hormone progesterone, such as mifepristone, are being evaluated to determine whether they can betaken to prevent development of breast cancer. However, it is important to know what impact taking these medicines has on the lining of the womb (endometrium), because changes in the endometrium can result in development of cancer. We gave mifepristone or a placebo to women with mutations in BRCA1 or BRCA2 for three months and examined tissue samples from the womb. We found that mifepristone caused periods to stop but did not increase cell growth or result in changes usually seen when cancer develops. These results suggest that short-term use of mifepristone is safe for the womb, but longer studies are needed to evaluate longer term effects. |\n| The biology and function of the endometrium are regulated by steroid hormones, and any imbalance in hormone signaling is associated with an increased risk of endometrial diseases. These conditions include endometrial hyperplasia, heavy menstrual bleeding, subfertility, endometriosis, | and endometrial cancer (EC)1–3. Estrogen (E) stimulates endometrial cell proliferation, whereas progesterone (P) inhibits their growth and promotes cell differentiation4. Consequently, elevated levels of E relative to P are associated with an increased risk ofdeveloping EC4,5. Globally, EC remained |  |\n\n","cbCaipwwXqtRSCOj","https://ap.wps.com/l/cbCaipwwXqtRSCOj","pdf",1863541,"English","# Abstract Plain language summary\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction (partial excerpt)\n## Endometrium regulation and risk\n## Hormonal imbalance and endometrial cancer\n## Rationale for progesterone receptor antagonism","[{\"question\":\"Why is mifepristone being studied for breast cancer prevention in BRCA1/2 pathogenic variant carriers?\",\"answer\":\"Progesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, especially in high-risk populations like BRCA1/2 pathogenic variant carriers.\"},{\"question\":\"What concern links mifepristone use to potential endometrial cancer risk?\",\"answer\":\"Because mifepristone can theoretically cause unopposed estrogen exposure in the setting of impaired DNA repair, it raises concerns about possible endometrial carcinogenesis.\"},{\"question\":\"What were the main short-term endometrial findings after three months of treatment?\",\"answer\":\"Mifepristone induced amenorrhea in treated participants without increasing epithelial cell proportions, and multi-omics analyses showed no molecular signatures consistent with oncogenic transformation; endometrial cancer–associated DNA methylation and gene expression indices stayed stable.\"}]","Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers | PDF",1790093124,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e18e55ae89905b0a0a1bfa11c5cbd352.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49228f6d07e57ff8e75e8309587fb2ca.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/867d9a2f9fa72fbe2e699e965dbba8e2.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dec224330487c46bcfcd6179cd9dd7f.webp",980,1301]